Mechanism of Action
MC2R Adrenal Stimulation
Tetracosactide binds MC2R (acth/" class="wiki-internal-link">ACTH receptor) on adrenocortical cells, coupling through Gs to increase cAMP and activate PKA. PKA stimulates rapid cortisol synthesis and release by: (1) upregulating StAR (steroidogenic acute regulatory protein) to transport cholesterol into mitochondria, (2) activating CYP11A1 (cholesterol side-chain cleavage enzyme), and (3) increasing gene expression of all steroidogenic enzymes over hours. The adrenal response peaks at 30-60 minutes and the 250 mcg dose maximally stimulates the adrenal cortex.
Diagnostic Utility
The standard short Synacthen test (SST) uses 250 mcg IV or IM tetracosactide, measuring cortisol at 0 and 30-60 minutes. A peak cortisol >550 nmol/L (18-22 mcg/dL depending on assay) is considered a normal response, indicating adequate adrenocortical reserve. The low-dose SST (1 mcg) is more sensitive for detecting subtle secondary adrenal insufficiency from pituitary disease. The test distinguishes primary (Addison's) from secondary (hypopituitary) causes by measuring ACTH before stimulation.
Anti-Inflammatory Effects
Like ACTH, tetracosactide exerts anti-inflammatory effects beyond simply increasing cortisol. It activates MC1R and MC3R on immune cells, directly reducing inflammatory cytokine production independent of cortisol. Depot tetracosactide used for infantile spasms and MS relapses may work partly through these direct alpha-msh/" class="wiki-internal-link">melanocortin anti-inflammatory pathways. This explains why ACTH analogues sometimes show efficacy in conditions where equivalent cortisol doses are less effective.
Research Summary
Adrenal Function Testing
Standard Clinical PracticeThe SST with 250 mcg cosyntropin is the most widely used test for adrenal insufficiency globally, with decades of validated reference ranges. It is used before initiating corticosteroid therapy (to exclude pre-existing AI), in suspected Addison disease, following pituitary surgery, and in patients on long-term glucocorticoid therapy assessing recovery. The 1 mcg low-dose variant is preferred by some centers for pituitary disease.
Infantile Spasms
Clinical UseDepot tetracosactide (Synacthen Depot) is one of two first-line treatments for infantile spasms (West syndrome), alongside vigabatrin. The mechanism appears to involve both cortisol-mediated CRH suppression (reducing abnormal brain excitability) and direct melanocortin actions on GABA and glutamate systems in the developing brain. Response rates of 40-80% are reported in various studies.
Nephrotic Syndrome
Clinical Use (some countries)Depot tetracosactide is used for steroid-resistant nephrotic syndrome in some European and Asian countries, with response rates comparable to cyclophosphamide in some series. The mechanism likely involves direct melanocortin effects on podocytes (renal filter cells that express MC1R and MC5R) beyond systemic immunosuppression.
Calculate your Tetracosactide dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Short Synacthen Test (standard) | 250 mcg IV or IM | Single dose; cortisol at 0/30/60 min | IV or IM |
| Low-dose SST | 1 mcg IV | Single dose; cortisol at 0/30 min | IV |
| Depot therapeutic (infantile spasms) | 0.5-1.5 mg/kg IM (varies by protocol) | Initially daily, then tapering | IM depot |
Standard diagnostic test is 250 mcg cosyntropin (IV or IM). Depot formulation requires specialist prescribing. Normal response: cortisol >550 nmol/L at 30 min.
Interactions
Safety Profile
Tetracosactide is generally well-tolerated for diagnostic use. Rare anaphylactic reactions (estimated 0.06%) can occur; allergy history should be assessed. Skin flushing, nausea, and brief blood pressure changes may follow rapid IV injection. Therapeutic depot use carries typical glucocorticoid side effects with prolonged use. WADA prohibits ACTH and analogues in sport due to performance-enhancing cortisol effects. Contraindicated in patients with known sensitivity to ACTH or those in whom cortisol elevation would be harmful.
References
- [1]Dickstein G, et al. Adrenocorticotropin stimulation test: effects of basal cortisol level, time of day, and suggested new sensitive low dose test. J Clin Endocrinol Metab. 1991.
- [2]Bue-Valleskey JM, et al. Cosyntropin (Cortrosyn): pharmacokinetics and pharmacodynamics. J Pharm Sci. 1998.
- [3]Baram TZ, et al. High-dose corticotropin (ACTH) versus prednisone for infantile spasms: a prospective, randomized, blinded study. Pediatrics. 1996.